TEST

  • 12/16/2022

    PAION AG issues statement on planned capital measure

  • 11/30/2022

    PAION AG announces change in Management Board

  • 11/16/2022

    Presentation Q3 2022

  • 11/16/2022

    PAION AG enters partnership with Viatris and expands sales activities in Europe

  • 11/16/2022

    PAION AG reports financial results for the first nine months of 2022

  • 11/14/2022

    PAION AG’S PARTNER TTY BIOPHARM RECEIVES MARKET APPROVAL FOR REMIMAZOLAM IN PROCEDURAL SEDATION IN TAIWAN

  • 08/31/2022

    PAION AG reports financial results for the first half-year 2022

  • 08/01/2022

    PAION LAUNCHES ERAVACYCLINE FOR THE TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTIONS IN ADULTS IN GERMANY

  • 06/24/2022

    ​​​​​​​PAION REPORTS SOLID PROGRESS WITH COMMERCIAL ACTIVITIES IN EUROPE

  • 05/25/2022

    ​​​​​​​PAION AG: ANNUAL GENERAL MEETING APPROVES ALL AGENDA ITEMS AND ELECTS MICHAEL SCHLENK AND GREGOR SIEBERT TO THE SUPERVISORY BOARD

  • 05/18/2022

    ​​​​​​​PAION AG PUBLISHES GROUP QUARTERLY STATEMENT FOR THE FIRST QUARTER OF 2022

  • 03/30/2022

    PAION AG ANNOUNCES CHANGE IN MANAGEMENT BOARD

  • 03/30/2022

    ​​​​​​​PAION AG REPORTS ON FISCAL YEAR 2021

  • 01/27/2022

    PAION AG ANNOUNCES CHANGE IN SUPERVISORY BOARD